LEVAQUIN by Johnson & Johnson is [see microbiology(12. Approved for moderate, severe infections caused by susceptible isolates of the designated microorganisms in the conditions listed in this section, nosocomial pneumonia due to methicillinsusceptible staphylococcus aureus and 36 more indications. First approved in 1996.
Drug data last refreshed 14h ago · AI intelligence enriched 1w ago
LEVAQUIN (levofloxacin) is a fluoroquinolone antibiotic administered intravenously or orally for moderate to severe bacterial infections. It treats nosocomial pneumonia, community-acquired pneumonia, acute bacterial sinusitis, skin/soft tissue infections, urinary tract infections, and chronic bacterial prostatitis caused by susceptible gram-positive and gram-negative organisms. The drug works by inhibiting bacterial DNA gyrase and topoisomerase IV, preventing DNA replication.
LEVAQUIN is in LOE-approaching lifecycle with moderate competitive pressure (30/100), indicating defensive brand positioning and potential focus on retention and lifecycle extension strategies.
[see Microbiology(12.4)]. 12.3 Pharmacokinetics The mean ±SD pharmacokinetic parameters of levofloxacin determined under single and steady-state conditions following oral tablet, oral solution, or intravenous (IV) doses of levofloxacin are summarized in Table 8. Table 8: Mean ±SD Levofloxacin PK…
Worked on LEVAQUIN at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.
LEVAQUIN offers limited career growth opportunity given its LOE-approaching status and minimal linked jobs (0). Roles available emphasize defending market share, managing payer relationships, and optimizing existing indication penetration rather than launching new therapies. This is appropriate for professionals seeking stability in a mature portfolio rather than high-growth trajectory.